Claire Y.J. Wenham, Michael McDermott and Philip G. Conaghan Pages 2206 - 2215 ( 10 )
Given the paucity of effective therapies and the increasing prevalence of osteoarthritis (OA) with ageing and overweight populations, new therapies for this painful, life-impairing condition are desperately needed, for both symptom relief and structural modification. With a growing understanding that OA involves multiple tissue pathologies including inflammation, many more therapeutic targets have been identified. This review will provide a current overview on the role of biologics in OA, including anti-tumour necrosis factor agents, growth factors and interleukin-1 antagonists.
Osteoarthritis, tumour necrosis factor, interleukin-1, growth factors, calcitonin gene related peptide, biologics.
, , Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Chapeltown Rd, Leeds LS7 4SA, UK.